Private Advisor Group’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Private Advisor Group’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-5,144	Closed	-$50K	–	2158
2022 Q2	$50K	Buy	5,144 +2,728	+113%	+$25.5K	﹤0.01%	2007
2022 Q1	$29K	Buy	+2,416	New	+$43.2K	﹤0.01%	2055
2020 Q3	–	Sell	-30	Closed	-$3K	–	3526
2020 Q2	$3K	Buy	+30	New	+$2.69K	﹤0.01%	3492

Other funds holding SYRS

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Private Advisor Group's SYRS Position: Q3 2022 in Review

Private Advisor Group sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q3 2022, closing a stake of 5,144 shares — an estimated $50K sold.

Private Advisor Group first reported a position in SYRS in Q2 2020 and held it in 3 quarters. The position peaked at $50K in Q2 2022. 53 funds tracked by Wall St. Rank hold SYRS as of Q3 2022.

Private Advisor Group reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Private Advisor Group sold 5,144 Syros Pharmaceuticals, Inc. Common Stock shares in Q3 2022, an estimated $50K.
Private Advisor Group first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2020 and held it in 3 quarters.
Private Advisor Group's Syros Pharmaceuticals, Inc. Common Stock position peaked at $50K in Q2 2022.
53 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q3 2022.

Based on Private Advisor Group's 13F filing for Q3 2022, filed 14 Oct 2022.